Microbiome Therapeutics Market Size, Share, and Trends 2025 to 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Microbiome Therapeutics Market 

5.1. COVID-19 Landscape: Microbiome Therapeutics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Microbiome Therapeutics Market, By Product Type

8.1. Microbiome Therapeutics Market Revenue and Volume Forecast, by Product Type

8.1.1. Probiotics

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Prebiotics

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Postbiotics

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Synbiotics

8.1.4.1. Market Revenue and Volume Forecast

8.1.5. Live Biotherapeutic Products (LBPs)

8.1.5.1. Market Revenue and Volume Forecast

8.1.6. Fecal Microbiota Transplantation (FMT)

8.1.6.1. Market Revenue and Volume Forecast

Chapter 9. Global Microbiome Therapeutics Market, By Therapeutic Application

9.1. Microbiome Therapeutics Market Revenue and Volume Forecast, by Therapeutic Application

9.1.1. Gastrointestinal Disorders (IBS, IBD, CDI, etc.)

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Metabolic Disorders (Obesity, Diabetes, NAFLD, etc.)

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Oncology (Cancer Immunotherapy Adjuncts, etc.)

9.1.3.1. Market Revenue and Volume Forecast

9.1.4. Autoimmune Disorders (Rheumatoid Arthritis, Multiple Sclerosis, etc.)

9.1.4.1. Market Revenue and Volume Forecast

9.1.5. Neurological Disorders (Parkinson’s, Autism, Depression, etc.)

9.1.5.1. Market Revenue and Volume Forecast

9.1.6. Other Applications (Dermatology, Infectious Diseases, etc.)

9.1.6.1. Market Revenue and Volume Forecast

Chapter 10. Global Microbiome Therapeutics Market, By Mode of Administration

10.1. Microbiome Therapeutics Market Revenue and Volume Forecast, by Mode of Administration

10.1.1. Oral

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Rectal (e.g., FMT Enemas, Colonoscopy Delivery)

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Topical

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Other Routes (e.g., Injectable, Nasal, etc.)

10.1.4.1. Market Revenue and Volume Forecast

Chapter 11. Global Microbiome Therapeutics Market, By End-User

11.1. Microbiome Therapeutics Market Revenue and Volume Forecast, by End-User

11.1.1. Hospitals & Specialty Clinics

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Research & Academic Institutes

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Homecare Settings

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Other End-Users (Contract Labs, CROs, etc.)

11.1.4.1. Market Revenue and Volume Forecast

Chapter 12. Global Microbiome Therapeutics Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by Product Type

12.1.2. Market Revenue and Volume Forecast, by Therapeutic Application

12.1.3. Market Revenue and Volume Forecast, by Mode of Administration

12.1.4. Market Revenue and Volume Forecast, by End-User

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by Product Type

12.1.5.2. Market Revenue and Volume Forecast, by Therapeutic Application

12.1.5.3. Market Revenue and Volume Forecast, by Mode of Administration

12.1.5.4. Market Revenue and Volume Forecast, by End-User

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by Product Type

12.1.6.2. Market Revenue and Volume Forecast, by Therapeutic Application

12.1.6.3. Market Revenue and Volume Forecast, by Mode of Administration

12.1.6.4. Market Revenue and Volume Forecast, by End-User

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by Product Type

12.2.2. Market Revenue and Volume Forecast, by Therapeutic Application

12.2.3. Market Revenue and Volume Forecast, by Mode of Administration

12.2.4. Market Revenue and Volume Forecast, by End-User

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by Product Type

12.2.5.2. Market Revenue and Volume Forecast, by Therapeutic Application

12.2.5.3. Market Revenue and Volume Forecast, by Mode of Administration

12.2.5.4. Market Revenue and Volume Forecast, by End-User

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by Product Type

12.2.6.2. Market Revenue and Volume Forecast, by Therapeutic Application

12.2.6.3. Market Revenue and Volume Forecast, by Mode of Administration

12.2.6.4. Market Revenue and Volume Forecast, by End-User

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by Product Type

12.2.7.2. Market Revenue and Volume Forecast, by Therapeutic Application

12.2.7.3. Market Revenue and Volume Forecast, by Mode of Administration

12.2.7.4. Market Revenue and Volume Forecast, by End-User

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by Product Type

12.2.8.2. Market Revenue and Volume Forecast, by Therapeutic Application

12.2.8.3. Market Revenue and Volume Forecast, by Mode of Administration

12.2.8.4. Market Revenue and Volume Forecast, by End-User

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by Product Type

12.3.2. Market Revenue and Volume Forecast, by Therapeutic Application

12.3.3. Market Revenue and Volume Forecast, by Mode of Administration

12.3.4. Market Revenue and Volume Forecast, by End-User

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by Product Type

12.3.5.2. Market Revenue and Volume Forecast, by Therapeutic Application

12.3.5.3. Market Revenue and Volume Forecast, by Mode of Administration

12.3.5.4. Market Revenue and Volume Forecast, by End-User

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by Product Type

12.3.6.2. Market Revenue and Volume Forecast, by Therapeutic Application

12.3.6.3. Market Revenue and Volume Forecast, by Mode of Administration

12.3.6.4. Market Revenue and Volume Forecast, by End-User

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by Product Type

12.3.7.2. Market Revenue and Volume Forecast, by Therapeutic Application

12.3.7.3. Market Revenue and Volume Forecast, by Mode of Administration

12.3.7.4. Market Revenue and Volume Forecast, by End-User

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by Product Type

12.3.8.2. Market Revenue and Volume Forecast, by Therapeutic Application

12.3.8.3. Market Revenue and Volume Forecast, by Mode of Administration

12.3.8.4. Market Revenue and Volume Forecast, by End-User

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by Product Type

12.4.2. Market Revenue and Volume Forecast, by Therapeutic Application

12.4.3. Market Revenue and Volume Forecast, by Mode of Administration

12.4.4. Market Revenue and Volume Forecast, by End-User

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by Product Type

12.4.5.2. Market Revenue and Volume Forecast, by Therapeutic Application

12.4.5.3. Market Revenue and Volume Forecast, by Mode of Administration

12.4.5.4. Market Revenue and Volume Forecast, by End-User

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by Product Type

12.4.6.2. Market Revenue and Volume Forecast, by Therapeutic Application

12.4.6.3. Market Revenue and Volume Forecast, by Mode of Administration

12.4.6.4. Market Revenue and Volume Forecast, by End-User

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by Product Type

12.4.7.2. Market Revenue and Volume Forecast, by Therapeutic Application

12.4.7.3. Market Revenue and Volume Forecast, by Mode of Administration

12.4.7.4. Market Revenue and Volume Forecast, by End-User

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by Product Type

12.4.8.2. Market Revenue and Volume Forecast, by Therapeutic Application

12.4.8.3. Market Revenue and Volume Forecast, by Mode of Administration

12.4.8.4. Market Revenue and Volume Forecast, by End-User

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by Product Type

12.5.2. Market Revenue and Volume Forecast, by Therapeutic Application

12.5.3. Market Revenue and Volume Forecast, by Mode of Administration

12.5.4. Market Revenue and Volume Forecast, by End-User

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by Product Type

12.5.5.2. Market Revenue and Volume Forecast, by Therapeutic Application

12.5.5.3. Market Revenue and Volume Forecast, by Mode of Administration

12.5.5.4. Market Revenue and Volume Forecast, by End-User

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by Product Type

12.5.6.2. Market Revenue and Volume Forecast, by Therapeutic Application

12.5.6.3. Market Revenue and Volume Forecast, by Mode of Administration

12.5.6.4. Market Revenue and Volume Forecast, by End-User

Chapter 13. Company Profiles

13.1. 4D Pharma plc

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial PerProduct Typeance

13.1.4. Recent Initiatives

13.2. AOBiome Therapeutics

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial PerProduct Typeance

13.2.4. Recent Initiatives

13.3. Axial Therapeutics, Inc.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial PerProduct Typeance

13.3.4. Recent Initiatives

13.4. Enterome SA

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial PerProduct Typeance

13.4.4. Recent Initiatives

13.5. Evelo Biosciences, Inc.

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial PerProduct Typeance

13.5.4. Recent Initiatives

13.6. Finch Therapeutics Group, Inc.

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial PerProduct Typeance

13.6.4. Recent Initiatives

13.7. MaaT Pharma

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial PerProduct Typeance

13.7.4. Recent Initiatives

13.8. Microbiotica Ltd.

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial PerProduct Typeance

13.8.4. Recent Initiatives

13.9. Novome Biotechnologies

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial PerProduct Typeance

13.9.4. Recent Initiatives

13.10. Quorum Innovations

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial PerProduct Typeance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms